A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PA / protective antigen

[Related PubMed/MEDLINE]
Total Number of Papers: 736
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PA  (>> Co-occurring Abbreviation)
Long Form:   protective antigen
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Canstatin-Derived Peptide Provides Insight into the Role of Capillary Morphogenesis Gene 2 in Angiogenic Regulation and Matrix Uptake. CMG2, MIDAS, VWA
2020 Atomic structures of anthrax toxin protective antigen channels bound to partially unfolded lethal and edema factors. EF, LF
2020 Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice. ---
2019 A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against B. anthracis Spores and Toxin. FIS
2019 A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses. EF, ELISA, LeTx, LF, MD, SDS-PAGE
2019 A Novel Supplementation Approach to Enhance Host Response to Sublingual Vaccination. EdTx, NEI
2019 A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model. ELISA, LT
2019 An ELISA using a recombinant chimera of protective antigen and lethal factor for serodiagnosis of cutaneous anthrax in India. CI, LF, NPV, PPV
2019 Analysis of a newly discovered antigen of Bacillus cereus biovar anthracis for its suitability in specific serological antibody testing. BA
10  2019 Bacillus anthracis Edema Toxin Inhibits Efferocytosis in Human Macrophages and Alters Efferocytic Receptor Signaling. cAMP, EF, ET
11  2019 Bacillus anthracis Protective Antigen Shows High Specificity for a UV Induced Mouse Model of Cutaneous Squamous Cell Carcinoma. CMG2, SCC, TEM8
12  2019 Bacillus anthracis Virulence Regulator AtxA Binds Specifically to the pagA Promoter Region. AtxA, PTS
13  2019 Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting. CLPA, MMP, uPA
14  2019 Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis. LF
15  2019 Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model. LF
16  2019 Development of a novel multiepitope chimeric vaccine against anthrax. BA, EF, LF
17  2019 Different mechanisms of two anti-anthrax protective antigen antibodies and function comparison between them. ---
18  2019 Effects of N-Glycosylation on the Structure, Function, and Stability of a Plant-Made Fc-Fusion Anthrax Decoy Protein. apo, BLI, ER, MD, SASA, TNA
19  2019 Evaluation of immune response to recombinant Bacillus anthracis LFD1-PA4 chimeric protein. EF, ELISA, LF, PCR, SDS-PAGE
20  2019 Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine. DCs
21  2019 Protective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax. ---
22  2019 Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax. ---
23  2019 Self-conjugated protective antigen elicits strong and durable protective antibody response against anthrax. GC, PEG, Tfh
24  2019 The biological role of the enigmatic C3larvinAB toxin of the honey bee pathogenic bacterium Paenibacillus larvae. ---
25  2019 Upstream sequence-dependent suppression and AtxA-dependent activation of protective antigens in Bacillus anthracis. ---
26  2019 Zeptomole per milliliter detection and quantification of edema factor in plasma by LC-MS/MS yields insights into toxemia and the progression of inhalation anthrax. EF, LF
27  2018 A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. CDC, mut
28  2018 A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis. ---
29  2018 A niosome formulation modulates the Th1/Th2 bias immune response in mice and also provides protection against anthrax spore challenge. NISV
30  2018 A serological survey of anthrax in domestic dogs in Zimbabwe: a potential tool for anthrax surveillance. ---
31  2018 Adjuvant Potential of Poly-alpha-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis. CFA, DDA-MPL, IL-2, PLG
32  2018 Analyzing Dynamic Protein Complexes Assembled On and Released From Biolayer Interferometry Biosensor Using Mass Spectrometry and Electron Microscopy. BLI, CMG2
33  2018 Anthrax protective antigen is a calcium-dependent serine protease. ---
34  2018 Bioinspired detoxification of blood: The efficient removal of anthrax toxin protective antigen using an extracorporeal macroporous adsorbent device. ---
35  2018 Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen. FDA's, NZW
36  2018 Effect of over expressing protective antigen on global gene transcription in Bacillus anthracis BH500. ---
37  2018 Establishment of a New Zealand White Rabbit Model for Lethal Toxin (LT) Challenge and Efficacy of Monoclonal Antibody 5E11 in the LT-Challenged Rabbit Model. LT, mAb
38  2018 Generation and screening of efficient neutralizing single domain antibodies (VHHs) against the critical functional domain of anthrax protective antigen (PA). ELISA
39  2018 Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax. ---
40  2018 Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model. FIS
41  2018 Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen. ---
42  2018 Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans. PK
43  2018 Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth. SVV, TEM8
44  2018 Serum-Mediated Cleavage of Bacillus anthracis Protective Antigen Is a Two-Step Process That Involves a Serum Carboxypeptidase. ---
45  2018 Simultaneous Immunodetection of Anthrax, Plague, and Tularemia from Blood Cultures by Use of Multiplexed Suspension Arrays. LODs
46  2018 Small molecule inhibitors of anthrax edema factor. EF, ET, FSBA
47  2018 TEM8 functions as a receptor for uPA and mediates uPA-stimulated EGFR phosphorylation. ---
48  2018 The Case for Human Serum as a Highly Preferable Sample Matrix for Detection of Anthrax Toxins. LF, LOD
49  2018 Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax. AVP, IM, s.c, Th, TMC-PA
50  2017 Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule. FDA
51  2017 Anthrax lethal toxin (LeTx) neutralization by PA domain specific antisera. EdTx, EF, LeTx, LF
52  2017 Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients. AVA, AVP, EF, ET
53  2017 Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential. EF, HER, LF, MAPK, NGFR, rLF, rPA
54  2017 Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation. LF
55  2017 Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae. Abs, hvKp, K1-CPS, mAbs, NETs
56  2017 Asymmetric Cryo-EM Structure of Anthrax Toxin Protective Antigen Pore with Lethal Factor N-Terminal Domain. LF
57  2017 Bacillus anthracis Edema Toxin Increases Fractional Free Water and Sodium Reabsorption in an Isolated Perfused Rat Kidney Model. cAMP, EF, ET, mAb, SEM
58  2017 Dynamic Phenylalanine Clamp Interactions Define Single-Channel Polypeptide Translocation through the Anthrax Toxin Protective Antigen Channel. EF, HBS, LF
59  2017 Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. AM, CMI, TB
60  2017 Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy. ---
61  2017 Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. LF, LT
62  2017 Protein catalyzed capture agents with tailored performance for in vitro and in vivo applications. PCC, VEGF
63  2017 Secondary Structure Preferences of the Anthrax Toxin Protective Antigen Translocase. LF
64  2017 Stability of domain 4 of the anthrax toxin protective antigen and the effect of the VWA domain of CMG2 on stability. AVA, CMG2, VWA
65  2017 Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins. AVA, CT, STING
66  2017 Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interaction. ---
67  2017 The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques. LD50, NHP, PEP
68  2017 The pag Gene of pXO1 Is Involved in Capsule Biosynthesis of Bacillus anthracis Pasteur II Strain. ---
69  2017 Use of the mice passive protection test to evaluate the humoral response in goats vaccinated with Sterne 34F2 live spore vaccine. TNA
70  2016 Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice. Ad, EF, LF, VHHs
71  2016 An internal standard approach for homogeneous TR-FRET immunoassays facilitates the detection of bacteria, biomarkers, and toxins in complex matrices. TR-FRET
72  2016 Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting. CMG2, PAD4, TEM8
73  2016 Anthrax Toxin-Expressing Bacillus cereus Isolated from an Anthrax-Like Eschar. ---
74  2016 Delivery of Non-Native Cargo into Mammalian Cells Using Anthrax Lethal Toxin. LF
75  2016 Development of a Sterne-Based Complement Fixation Test to Monitor the Humoral Response Induced by Anthrax Vaccines. CFT, EF, LF
76  2016 Diminished but Not Abolished Effect of Two His351 Mutants of Anthrax Edema Factor in a Murine Model. AC, EF, ET
77  2016 Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity. ---
78  2016 Expression and refolding of the protective antigen of Bacillus anthracis: A model for high-throughput screening of antigenic recombinant protein refolding. ---
79  2016 Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model. IFN-gamma, IL-10, IL-2, IL-4, LeTx, LF, TNF-alpha
80  2016 Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. AVA, CMI, IFN-gamma, IL-4, IM, MBCs, SI, TNA, TNF-alpha
81  2016 Identification of the pXO1 plasmid in attenuated Bacillus anthracis vaccine strains. ---
82  2016 Molecular assembly of lethal factor enzyme and pre-pore heptameric protective antigen in early stage of translocation. ATR, MD
83  2016 Multivalent Chromosomal Expression of the Clostridium botulinum Serotype A Neurotoxin Heavy-Chain Antigen and the Bacillus anthracis Protective Antigen in Lactobacillus acidophilus. ---
84  2016 Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-The first step toward a rationally designed anthrax vaccine. AVA
85  2016 Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat. EF, ET, l-NAME, MAP, MCF, NO, PE
86  2016 Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. ---
87  2016 Pharmacology and Anti-infective Role of Raxibacumab: A Novel Monoclonal Antibody for the Treatment of Anthrax. B. anthracis, LF
88  2016 Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease. AVA, NEAT
89  2016 Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R. AT, B. anthracis, EF, ET, LF, LT
90  2016 Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor. CMG2, HSA, VWA
91  2016 Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax. EF, LF
92  2016 Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane Insertion and Pore Formation. ANTXR2, Ig
93  2016 Soluble Expression and Characterization of Biologically Active Bacillus anthracis Protective Antigen in Escherichia coli. ---
94  2016 Structure of anthrax lethal toxin prepore complex suggests a pathway for efficient cell entry. cryo-EM, EF, LF
95  2016 Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination. AE, AVA, CI, LLRs, OR, SRs
96  2016 Use of Multiple Peptide-Based SERS Probes Binding to Different Epitopes on a Protein Biomarker To Improve Detection Sensitivity. AuNP, LOD, SERS
97  2016 [Efficient expression of anthrax edema factor in Escherichia coli and its single-step purification]. EF
98  2016 [Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice]. EF, ET, LF, LT, mAbs
99  2015 A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model. PA63, VHHs
100  2015 Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. LVX